The pattern in trials has been broadly consistent with other incretin-based therapies (such as Mounjaro and Wegovy), and most side effects have been mild to moderate and dose-dependent, occurring mainly during the initial dose-escalation period
We will do this by adjusting your dosing every month to achieve that goal if tolerated
Dosing adjustments are based on real clinical signals rather than rigid schedules
Patients with elevated cardiac risk often experience measurable benefits
doi: 10.3390/nu7115440 91 CanforaEEvan der BeekCMJockenJWEGoossensGHHolstJJOlde DaminkSWMet al
Data were analysed using one-way ANOVA with Bonferroni post hoc multiple-comparison test ( b , d , h , k , m , o , p ), two-way repeated-measures ANOVA ( a , c , e g , j , l ) or Kruskall-Wallis test with uncorrected Dunnss test ( i , n )